Peter Joe Pitts
Director/Board Member at Painscript Corp.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Stephen John Kiel | M | 71 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 4 years |
Jun Cai Bai | M | 61 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 4 years |
Julie Dobson | F | 67 |
Painscript Corp.
Painscript Corp. Internet Software/ServicesTechnology Services Part of Optimus Healthcare Services, Inc., Painscript Corp. is a medical treatment compliance platform that focuses on creating personalized pathways to support chronic care management interventions for patients suffering from opioid and other substance use disorders. The company is based in Rockville, MD. The platform is technology-based and clinically validated through nine separate published and peer-reviewed clinical trials. Painscript's approach is accessible and user-friendly via a digital platform, providing physicians and patients with daily, evidence-based telehealth monitoring interventions designed to improve patient compliance with treatment protocols, leading to better health outcomes and a reduction in related healthcare costs. Daniel L. Cohen has been the CEO of the company since 2019. Painscript was acquired by Optimus Healthcare Services, Inc. on March 24, 2021 for $4.50 million. | - |
Ernest Stern | M | 73 |
Painscript Corp.
Painscript Corp. Internet Software/ServicesTechnology Services Part of Optimus Healthcare Services, Inc., Painscript Corp. is a medical treatment compliance platform that focuses on creating personalized pathways to support chronic care management interventions for patients suffering from opioid and other substance use disorders. The company is based in Rockville, MD. The platform is technology-based and clinically validated through nine separate published and peer-reviewed clinical trials. Painscript's approach is accessible and user-friendly via a digital platform, providing physicians and patients with daily, evidence-based telehealth monitoring interventions designed to improve patient compliance with treatment protocols, leading to better health outcomes and a reduction in related healthcare costs. Daniel L. Cohen has been the CEO of the company since 2019. Painscript was acquired by Optimus Healthcare Services, Inc. on March 24, 2021 for $4.50 million. | - |
Chong Sun Chung | M | 48 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 3 years |
Martin Mann | M | - |
Painscript Corp.
Painscript Corp. Internet Software/ServicesTechnology Services Part of Optimus Healthcare Services, Inc., Painscript Corp. is a medical treatment compliance platform that focuses on creating personalized pathways to support chronic care management interventions for patients suffering from opioid and other substance use disorders. The company is based in Rockville, MD. The platform is technology-based and clinically validated through nine separate published and peer-reviewed clinical trials. Painscript's approach is accessible and user-friendly via a digital platform, providing physicians and patients with daily, evidence-based telehealth monitoring interventions designed to improve patient compliance with treatment protocols, leading to better health outcomes and a reduction in related healthcare costs. Daniel L. Cohen has been the CEO of the company since 2019. Painscript was acquired by Optimus Healthcare Services, Inc. on March 24, 2021 for $4.50 million. | - |
Craig Marshall Lea | M | 71 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 3 years |
Bruce A. Kehr | M | - |
Painscript Corp.
Painscript Corp. Internet Software/ServicesTechnology Services Part of Optimus Healthcare Services, Inc., Painscript Corp. is a medical treatment compliance platform that focuses on creating personalized pathways to support chronic care management interventions for patients suffering from opioid and other substance use disorders. The company is based in Rockville, MD. The platform is technology-based and clinically validated through nine separate published and peer-reviewed clinical trials. Painscript's approach is accessible and user-friendly via a digital platform, providing physicians and patients with daily, evidence-based telehealth monitoring interventions designed to improve patient compliance with treatment protocols, leading to better health outcomes and a reduction in related healthcare costs. Daniel L. Cohen has been the CEO of the company since 2019. Painscript was acquired by Optimus Healthcare Services, Inc. on March 24, 2021 for $4.50 million. | - |
Sergey V. Sheleg | M | - |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | 22 years |
Daniel Cohen | M | 65 |
Painscript Corp.
Painscript Corp. Internet Software/ServicesTechnology Services Part of Optimus Healthcare Services, Inc., Painscript Corp. is a medical treatment compliance platform that focuses on creating personalized pathways to support chronic care management interventions for patients suffering from opioid and other substance use disorders. The company is based in Rockville, MD. The platform is technology-based and clinically validated through nine separate published and peer-reviewed clinical trials. Painscript's approach is accessible and user-friendly via a digital platform, providing physicians and patients with daily, evidence-based telehealth monitoring interventions designed to improve patient compliance with treatment protocols, leading to better health outcomes and a reduction in related healthcare costs. Daniel L. Cohen has been the CEO of the company since 2019. Painscript was acquired by Optimus Healthcare Services, Inc. on March 24, 2021 for $4.50 million. | 5 years |
Ling Yang | F | 44 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 4 years |
Michael William Pennington | M | 62 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 3 years |
Xiao Bo Lu | M | 51 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 3 years |
Shing Cheung Wong | M | 37 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | - |
Hao Zhang | M | 42 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 4 years |
Timothy Nieters | M | 52 |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | 9 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Wolfgang Blättchen | M | 71 |
McGill University
| 9 years |
Bill Stanimir | M | - |
McGill University
| 8 years |
Nathan M. Stubina | M | 65 |
McGill University
| 6 years |
Ali Vojdani | M | - |
McGill University
| 4 years |
Teck Cheong Ho | M | 65 |
McGill University
| 6 years |
Michel Léonard | M | 66 |
McGill University
| 7 years |
Hosen S. Marjaee | M | - |
McGill University
| 5 years |
Richard Duke | M | - |
McGill University
| 8 years |
Christopher Theodoropoulos | M | 69 |
McGill University
| 4 years |
Neil Wiener | M | - |
McGill University
| 7 years |
Jean-Pierre Landry | M | - |
McGill University
| 4 years |
Luigi Fraquelli | M | - |
McGill University
| 6 years |
André Chabot | M | - |
McGill University
| 5 years |
Hubert Lacroix | M | 68 |
McGill University
| 8 years |
Peter Krogh Jensen | M | 72 |
McGill University
| 7 years |
Michael Arnkvarn | M | - |
McGill University
| 4 years |
Beena Goldenberg | F | 61 |
McGill University
| 3 years |
Brian Conway | M | - |
McGill University
| 4 years |
Jacques A. Nadeau | M | - |
McGill University
| 2 years |
Howard Feldman | M | - |
McGill University
| 4 years |
Callum Grant | M | - |
McGill University
| 1 years |
Peter G. Wilson | M | 61 |
McGill University
| 4 years |
Robert A. Kozlov | M | - |
McGill University
| 4 years |
Brian R. Mitchell | M | - |
McGill University
| 4 years |
Scott Jones | M | 68 |
McGill University
| 4 years |
Hyman M. Schipper | M | - |
McGill University
| 3 years |
Yoke Keong Yong | M | 64 |
McGill University
| 4 years |
Zoltan J. Cendes | M | 77 |
McGill University
| 2 years |
David Neuburger | M | 65 |
McGill University
| 4 years |
Sean Languedoc | M | - |
McGill University
| 3 years |
François Caza | M | - |
McGill University
| 4 years |
Ke Jun Li | M | 73 |
McGill University
| 2 years |
David Sloan | M | 67 |
McGill University
| 4 years |
Bruno Lamarche | M | - |
McGill University
| 4 years |
Edward Sellers | M | - |
McGill University
| 3 years |
Bruce Fischer | M | 66 |
McGill University
| 4 years |
Blake Anderson | M | - |
McGill University
| 4 years |
Matt S. Galvez | M | - |
McGill University
| 4 years |
Sophie Soelaiman | F | 63 |
McGill University
| 4 years |
George J. Economy | M | - |
McGill University
| 4 years |
William Kaldis | M | - |
McGill University
| 4 years |
Victor Taboika | M | - |
McGill University
| 4 years |
Salvatore Reda | M | - |
McGill University
| 4 years |
Beni Prananto | M | 65 |
McGill University
| 1 years |
Lito Ioannidou | F | 70 |
McGill University
| 2 years |
Ricky Chan | M | 65 |
McGill University
| 4 years |
Martin Labrecque | M | - |
McGill University
| 4 years |
Patricia P. Brister | F | 77 |
McGill University
| 4 years |
Tom Czitron | M | 66 |
McGill University
| 4 years |
Robert Wares | M | 66 |
McGill University
| 4 years |
Daryl Fridhandler | M | 67 |
McGill University
| 4 years |
Sidney Horn | M | 73 |
McGill University
| 3 years |
Richard Alan Walls | M | 76 |
McGill University
| 3 years |
Julian Adams | M | 69 |
McGill University
| 4 years |
Peter Hanford | M | - |
McGill University
| 4 years |
Alec Walsh | M | - |
McGill University
| 4 years |
Carmine de Somma | M | - |
McGill University
| 4 years |
Maryse Bertrand | F | 65 |
McGill University
| 4 years |
Mathieu Gauvin | M | - |
McGill University
| 4 years |
Michael Carter Shannon | M | - |
McGill University
| 4 years |
Robert Coallier | M | 63 |
McGill University
| 4 years |
David McAusland | M | 69 |
McGill University
| 4 years |
Kevin John Elliott | M | - |
McGill University
| 4 years |
Linda Arey Skladany | F | 79 |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | 1 years |
Kenneth Silver | M | 64 |
McGill University
| 2 years |
Pierre Leroux | M | - |
McGill University
| 4 years |
John Gocek | M | - |
McGill University
| 4 years |
Michael Frank | M | - |
McGill University
| 4 years |
Marc Tessier-Lavigne | M | 64 |
McGill University
| 4 years |
Richard M. Yanofsky | M | 65 |
McGill University
| 4 years |
Andrew Gertler | M | 61 |
McGill University
| 4 years |
Ronald Amstutz | M | - |
McGill University
| 4 years |
Brenda R. Lazare | F | - |
McGill University
| 4 years |
Gregory Gubitz | M | 66 |
McGill University
| 4 years |
Robert Lande | M | 61 |
McGill University
| 4 years |
Mitchell I. Rosen | M | 63 |
McGill University
| 4 years |
Giuseppe Calabrese | M | - |
McGill University
| 3 years |
Jean-François Perrault | M | - |
McGill University
| 4 years |
Philippe Giaro | M | 59 |
McGill University
| 4 years |
Claude Michaud | M | - |
McGill University
| 4 years |
Stephen William Kibsey | M | - |
McGill University
| 6 years |
William R. Walker | M | - |
McGill University
| 4 years |
Guy Chamberland | M | - |
McGill University
| 4 years |
Mitchell L. Greenspoon | M | 63 |
McGill University
| 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 83 | 83.00% |
Cayman Islands | 10 | 10.00% |
United States | 7 | 7.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter Joe Pitts
- Personal Network